Clinical and laboratory features at diagnosis of 132 patients with prefibrotic myelofibrosis compared with those with primary myelofibrosis-fibrotic type.

§<p>P value refers to the difference between prefibrotic myelofibrosis and myelofibrosis-fibrotic type;</p>§§<p>P value refers to the difference between prefibrotic myelofibrosis and myelofibrosis-fibrotic type with bone marrow (BM) fibrosis grade 1;</p>§§§<p>P value refers to the difference between myelofibrosis-fibrotic type with BM fibrosis grade 1 and with BM fibrosis grade 2 or 3;</p>*<p>White-blood cell (WBC) count was corrected for the number of circulating erythroblasts;</p>**<p>Spleen index is the product of the longitudinal by the transverse spleen axis, the latter defined as the maximal width of the organ.</p

Survival of patients with primary myelofibrosis.

<p>Patients were categorized according they were diagnosed with prefibrotic myelofibrosis, myelofibrosis-fibrotic type with early bone marrow fibrosis (grade 1) or myelofibrosis-fibrotic type with advanced bone marrow fibrosis (grade 2 or 3).</p

Odds ratio to have aminotransferase elevations in <i>MYH9</i>-RD patients as compared with the three control populations.

<p>Data represent ORs (95% CIs).</p><p>N.A. = not available</p><p>Note:</p>1<p> = Calculation of the OR is not possible since none of the 77 analysed ITP patients presented an elevation of AST.</p

Genetic analysis of the 75 <i>MYH9</i>-RD patients described in this study.

<p>Abbreviations: Ref. = references.</p

Prevalence of liver enzyme alterations in the analyzed patient populations.

<p>Data are presented as n° of patients with altered value/total n° of evaluable patients (%).</p><p>N.A. = not available.</p

Demographic characteristics of the study populations.

<p>Demographic characteristics of the study populations.</p

Immunohistochemistry for NMMHC-IIA in the liver biopsy from one patient with MYH9-RD.

<p>Liver biopsy from a 10-years-old patient with MYH9-RD caused by the p.T1155A mutation of MYH9 with persistently elevated AST, ALT and GGT. (A, B): Immunohistochemistry for NMMHC-IIA showed a signal (brown, horseradish peroxidase staining) concentrated close to the hepatocytes' plasma membrane. The distribution of NMMHC-IIA was not significantly different from that from a healthy control (C, D). Specimens were counterstained with Meyer's haematoxylin. Scale bars correspond to 10 µm.</p

Frequency of abnormal liver tests depending on the location of the MYH9 gene mutation.

<p>Mutations involving the motor domain and tale domain regions of the gene are indicated. No significant differences in the distribution of liver test alteration between the two locations of the gene defect were evident.</p

Sensitivity, Specificity, and Cut-off Value for the Ability of Hematological Parameters to Identify Patients with Increased Frequency of ECFCs.

<p>AUC = Area under the curve.</p

Participant Characteristics, by Diagnostic Category.

<p>SVT = Splanchnic vein thrombosis.</p>*<p>The group consisted in 38 patients with diagnosis of polycythemia vera and 21 patients with diagnosis of essential thrombocythemia.</p>§<p>Bone marrow fibrosis was graded according EUMNET criteria¹⁸ Bone marrow biopsy was evaluated at the time of ECFCs assay in 72 patients with a diagnosis of primary myelofibrosis and 31 with a diagnosis of prefibrotic myelofibrosis.</p